Lyell Immunopharma (LYEL) Net Margin (2020 - 2026)
Lyell Immunopharma (LYEL) reported Net Margin of 5160800.0% for Q1 2026, down 331961429.0% on a YoY basis from N/an in Q1 2025, and down 114.0% sequentially from 2411550.0% in Q4 2025.
Lyell Immunopharma (LYEL) Net Margin (2020 - 2026) Analysis & Trends
Lyell Immunopharma (LYEL) has 7 years of Net Margin data on file, last reported at 5160800.0% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin fell 331961429.0% year-over-year to 5160800.0%; the trailing twelve-month figure through Mar 2026 stood at 1501754.84% (down 4971484.0% YoY), and the FY2025 full-year result was 795952.78%, up 38078493.0% from the prior year.
- Net Margin declined to 5160800.0% in Q1 2026, from 2411550.0% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 363.66% in Q2 2022 to a low of 6279266.67% in Q3 2022.
- A 5-year average of 1759653.49% and a median of 995992.31% in 2024 frame the typical range for Net Margin.
- Across the five-year window, Net Margin tumbled 627706536 bps in 2022 and soared 599906667 bps in 2023, its largest moves.
- Tracing LYEL's Net Margin over 5 years: stood at 397.88% in 2022, then tumbled by 593121 bps to 2360315.38% in 2023, then sank by 116 bps to 5100509.09% in 2024, then surged by 53 bps to 2411550.0% in 2025, then plunged by 114 bps to 5160800.0% in 2026.
- Business Quant data shows LYEL's Net Margin at 5160800.0% in Q1 2026, 2411550.0% in Q4 2025, and 681120.0% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 15.02% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 28.20% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Lyell Immunopharma | 276.08 Mn | 276.08 Mn | - | -5,160,800.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5,160,800.00% |
| Dec 31, 2025 | -2,411,550.00% |
| Sep 30, 2025 | -681,120.00% |
| Jun 30, 2025 | -1,443,337.50% |
| Mar 31, 2025 | -1,841,185.71% |
| Dec 31, 2024 | -5,100,509.09% |
| Sep 30, 2024 | -365,905.88% |
| Jun 30, 2024 | -995,992.31% |
| Mar 31, 2024 | -2,496,966.67% |
| Dec 31, 2023 | -2,360,315.38% |
| Sep 30, 2023 | -280,200.00% |
| Jun 30, 2023 | -336,318.52% |
| Mar 31, 2023 | -128,167.69% |
| Dec 31, 2022 | -397.88% |
| Sep 30, 2022 | -6,279,266.67% |
| Jun 30, 2022 | -363.66% |
| Mar 31, 2022 | -31,712.30% |
| Dec 31, 2021 | -6,248.12% |
| Sep 30, 2021 | -2,201.31% |
| Jun 30, 2021 | -6,617.35% |